Tvardi Therapeutics, Inc. (TVRD) stock forecast and price target
Price $1.18 · data as of November 13, 2026
12-month price target
Average target$8.88
Upside / downside+652.1%
Analysts8
ConsensusBuy
Low $3.00Average $8.88High $14.00
Gold marker: average target · white marker: today’s price ($1.18)
Analyst ratings
Strong buy 2Buy 5Hold 1Sell 0Strong sell 1
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.26 | +8.2% | $0 |
| Next fiscal year ends December 31, 2027 | $-2.03 | +10.2% | $0 |
| Next quarter ends December 31, 2026 | $-0.42 | +46.5% | $0 |
| Quarter after ends March 31, 2027 | $-0.35 | — | $0 |
Consensus of the analysts covering Tvardi Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Tvardi Therapeutics stock price target?
The average 12-month target from 8 analysts is $8.88, 652.1% above the current price of $1.18 Targets range from $3.00 to $14.00.
Is Tvardi Therapeutics a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 5 buy, 1 hold, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Tvardi Therapeutics expected to earn?
Analysts expect EPS of $-2.26 for the fiscal year ending December 31, 2026 and $-2.03 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.